Valneva/$VALN

1D1W1MYTD1Y5YMAX

About Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Ticker
$VALN
Sector
Health
Primary listing
NASDAQ
Employees
620
Headquarters
Saint-Herblain, France
Website
valneva.com

Valneva Metrics

BasicAdvanced
$614M
-
-$1.01
1.37
-

Bulls say / Bears say

The Pfizer-partnered Lyme vaccine delivered more than 70% efficacy in Phase 3, and the EMA validated its marketing-authorization application on August 14, 2026, creating a potentially transformative regulatory catalyst for Valneva. (Pfizer)
Liquidity has improved ahead of the Lyme regulatory process: cash reached €121.5 million at June 30, 2026, including €37 million from the reserved offering, while restructuring is expected to improve profitability and cash flow in the second half. (SEC filing)
Valneva retains multiple growth options beyond Lyme, with additional IXIARO deliveries to the U.S. Department of Defense expected during 2026 and Phase 2 results for its S4V2 Shigella vaccine candidate expected in the third quarter. (SEC filing)
Valneva’s first-half 2026 revenue fell to €65.8 million from €97.6 million, while net loss widened to €63.3 million from €20.8 million and adjusted EBITDA loss reached €40.1 million. (SEC filing)
IXCHIQ remains a material weakness: first-half sales declined to €4.4 million, gross margin was deeply negative because of €9.7 million in manufacturing-contract cancellation fees and a €4.5 million inventory impairment, while the EMA narrowed its use to high-risk individuals aged 12 and older. (SEC filing; EMA)
The Lyme vaccine’s efficacy is encouraging but regulatory risk remains: the first prespecified analysis did not meet its statistical criterion because the 95% confidence-interval lower bound was below 20, leaving approval and commercialization dependent on regulators accepting the secondary analysis. (Pfizer)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.

Valneva News

AllArticlesVideos

Valneva Q2 Earnings Call Highlights

MarketBeat1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.